skip to Main Content

Innovative PCR test to rapid detection of 15 high-risk HPV strains


Geneme Sp. z o.o.

Local Partner:
Georgian Organization of Cancer Research

Total budget:
US$ 71,413

Requested budget:
US$ 40,000

Time Frame:
25.03.2022 – 20.09.2022

According to WHO data 10-20% of people aged 15-49 are infected with HPV worldwide, including almost 40% of women under 25. Cervical cancer which is caused largely by HPV virus is the second most common in women under 45 and the third most fatal in women, after breast and lung cancer.

Solution: GeneMe intends to develop an innovative, fast and accurate test to identify carcinogenic HPV strains in potentially infected individuals. The diagnostic tool that allows for the qualitative detection and identification of 15 high-risk HPV genotypes. The test will be based on PCR with fluorescence detection and can be performed on a commercially available PCR equipment. The test will make no more 30 minutes to run and will give an extremely reliable result.


Back To Top